NSE/NIVABUPA

NIVABUPANIVABUPA

NSE Equity · NSE

₹80.11+2.05%

52-wk low52-WEEK RANGE52-wk high

₹68.4+17.1% from low ·-13.3% from high₹92.35

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

NIVABUPA+8.95% · 1Y

Range high ₹95.21Range low ₹67.5Latest ₹80.11252 bars · daily-close · NSE bhavcopy + 10Y history

NSE EquityInsurance - LifeMidcap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite25/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return +2.7%
· Below 200-DMA (-0.4%) — downtrend

Valuation

High

Looks expensive vs the sector.

· P/B 4.05 above sector median

Growth

High

Growing faster than the broader market.

· Revenue YoY +65.8% — strong top-line
· Profit YoY +167.8% — strong earnings growth

Profitability

Low

Profitability is a concern.

· ROE 8.0% — weak returns on equity
· Net margin 3.9% — thin margins

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeC(51/100)

Durability

71/100

Reasonable financial health; watch the weaker inputs.

Show 2 drivers

Debt/Equity0.07 (100pt)
ROE8.0% (32pt)

Valuation

20/100

Richly valued on most axes; limited margin of safety.

Show 2 drivers

P/B4.05 (24pt)
EV/EBITDA32.4 (15pt)

Momentum

61/100

Constructive setup — momentum building, not extended.

Show 5 drivers

52w change+2.7% (48pt)
DMA-trend alignmentup (75pt)
RSI (14)75.3 (65pt)
Price vs 200-DMA+2.3% (50pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/B4.05

FAIR

CheapestP/B 4.05 at 65th %ile of sector.Most expensive

EV/EBITDA32.42

OVERVALUED

CheapestEV/EBITDA 32.4 — expensive on EV basis.Most expensive

Monthly seasonality

Avg monthly return over 2 years · historical — not a forecast

Best: May +13.11% · Worst: Jun -11.40%

Jan

+0.5%

50% win

Feb

-7.4%

0% win

Mar

+0.3%

50% win

Apr

+9.3%

100% win

May

+13.1%

100% win

Jun

-11.4%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 1

Lean balance sheet (D/E 0.07)
Low leverage means earnings are less sensitive to rate cycles

WEAKNESSES · 1

Low return on equity (8.0%)
Below 10% ROE suggests inefficient use of shareholder capital

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 1

RSI overbought at 75
Above 75 often precedes consolidation or short-term pullbacks

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+2.1%

+8.7%

+10.8%

+0.7%

-2.1%

+9.7%

—

10Y

—

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
NIVABUPATHIS Niva Bupa Health Insurance Company Limited	₹80.11	+2.7%	14,338	—	4.05	8.0%	0.07	+65.8%
ABCAPITAL Aditya Birla Capital Limited	₹340.4	+68.1%	89,888	25.8	2.79	10.8%	4.60	+17.6%
ABBOTINDIA Abbott India Limited	₹25,785	-16.6%	54,547	35.8	13.60	38.0%	0.04	+9.6%
360ONE 360 ONE WAM LIMITED	₹1,113.3	+16.7%	44,744	38.7	4.77	12.3%	1.47	+35.0%
3MINDIA 3M India Limited	₹31,410	+4.4%	35,158	92.9	21.83	23.5%	0.06	+6.1%
AADHARHFC Aadhar Housing Finance Limited	₹496.45	+3.5%	21,173	20.8	3.05	14.6%	2.55	—
ABDL Allied Blenders and Distillers Limited	₹573.8	+76.4%	16,176	60.4	10.70	17.7%	0.67	+5.8%
AAVAS Aavas Financiers Limited	₹1,347.9	-37.8%	10,612	17.1	2.26	13.3%	3.08	+13.3%
63MOONS 63 moons technologies limited	₹662.7	-9.8%	8,006	—	0.92	-0.2%	0.00	-6.3%

ASK AXEL

Dig deeper into NIVABUPA

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for NIVABUPA — all in one sourced reply.

Ask free in chat

Run these tools on NIVABUPA

Historical return →

"If I had bought NIVABUPA in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on NIVABUPA

Brokerage + charges →

All-in cost for trading NIVABUPA

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	-0.34	-0.47	-38.2%
-2q	-0.23	-0.19	+17.4%
-3q	-0.38	-0.50	-31.6%
-4q	1.25	1.11	-11.2%

NIVABUPANIVABUPA

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Analyst consensus

Company + balance sheet snapshot

Peer comparison · Other

Ask Axel about NIVABUPA

Recent news

Dig deeper into NIVABUPA

Run these tools on NIVABUPA

Technical snapshot

Earnings history + surprises

Recent news

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Fundamentals

Pros and cons

Sector-relative context

Analyst consensus

Company + balance sheet snapshot

Peer comparison · Other